Sobi publishes report for the third quarter 2021
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the third quarter 2021. Total revenue amounted to SEK 3,761 M, a 29 per cent growth at CER compared with the same period 2020. EBITA was SEK 1,166 M, resulting in an EBITA margin of 31 per cent.
July – September
- Total revenue SEK 3,761 M (2,970), +27 per cent, +29 per cent at constant exchange rates (CER)
- Haematology revenue SEK 2,291 M (2,147), +9 per cent at CER of which Elocta® SEK 1,035 M (1,115), -6 per cent at CER, Alprolix® SEK 430 M (435), unchanged at CER, and Doptelet® SEK 400 M (145), +187 per cent at CER
- Immunology revenue SEK 1,144 M (619), +89 per cent at CER of which Kineret® SEK 516 M (463), +13 per cent at CER, Synagis® SEK 374 M (46), +769 per cent at CER, and Gamifant® SEK 255 M (110), +139 per cent at CER
- EBITA1 SEK 1,166 M (933), EBITA margin1 31 per cent (31)
- Earnings per share (EPS) before dilution SEK 1.60 (0.94)
- Cash flow from operating activities SEK 257 M (381)
January – September
- Total revenue SEK 10,633 M (10,680), unchanged and +7 per cent at CER
- Haematology revenue SEK 6,294 M (6,578), +1 per cent at CER of which Elocta SEK 2,896 M (3,514), -14 per cent at CER, Alprolix SEK 1,281 M (1,286), +4 per cent at CER, and Doptelet SEK 810 M (396), +126 per cent at CER
- Immunology revenue SEK 3,450 M (3,133), +21 per cent at CER, of which Kineret SEK 1,608 M (1,493), +16 per cent at CER, Synagis SEK 1,286 M (1,294), +13 per cent at CER, and Gamifant SEK 556 M (346), +78 per cent at CER
- EBITA1 SEK 3,572 M (4,124), EBITA margin1 34 per cent (39)
- EPS before dilution SEK 4.87 (5.92)
- Cash flow from operating activities SEK 3,349 M (4,209)
Significant events after the reporting period
- Aspaveli® (pegcetacoplan) for PNH: positive CHMP opinion in the EU
Financial outlook 2021 – refined
- Revenue for the full year 2021 is expected to be in the range of SEK 14,500–15,000 M
- EBITA margin is expected to be in the range of 33–35 per cent of revenue
Guido Oelkers, CEO and President:
“We saw continued growth and pipeline progress in the third quarter of 2021, and it is satisfying to see that results are confirming our strategic direction. Overall, our two main business areas are in solid shape and they progressed as expected.”
Financial Summary
| Q3 | Q3 | Jan-Sep | Jan-Sep | Full-year | |||
| SEK M | 2021 | 2020 | Change | 2021 | 2020 | Change | 2020 |
| Total revenue | 3,761 | 2,970 | 27% | 10,633 | 10,680 | 0% | 15,261 |
| Gross profit | 2,802 | 2,339 | 20% | 8,165 | 8,318 | -2% | 12,036 |
| Gross margin1 | 75% | 79% | 77% | 78% | 79% | ||
| EBITA1 | 1,166 | 933 | 25% | 3,572 | 4,124 | -13% | 6,700 |
| EBITA adjusted1,2 | 1,166 | 933 | 25% | 3,572 | 4,124 | -13% | 6,301 |
| EBITA margin1 | 31% | 31% | 34% | 39% | 44% | ||
| EBITA margin adjusted1,2 | 31% | 31% | 34% | 39% | 41% | ||
| Profit for the period | 473 | 278 | 70% | 1,438 | 1,743 | -18% | 3,245 |
| Earnings per share, before dilution, SEK | 1.60 | 0.94 | 70% | 4.87 | 5.92 | -18% | 11.01 |
| Earnings per share, before dilution, SEK adjusted1,2,3 | 1.60 | 0.94 | 70% | 4.87 | 5.92 | -18% | 9.66 |
| 1Alternative Performance Measures (APMs). 2 EBITA in 2020 excluding non-recurring items; other operating income related to the reversal of the CVR liability of SEK 399 M. 3EPS in full-year 2020 excluding the reversal of the CVR liability of SEK 399 M. |
|||||||
Contacts
Thomas Kudsk Larsen
Head of Communication and Investor Relations
Maria Kruse
Director of Communication and Investor Relations
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology, and specialty indications. Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia, and Asia. In 2020, Sobi’s revenues amounted to SEK 15.3 billion. Sobi’s share (STO: SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.
Swedish Orphan Biovitrum AB (publ)
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00 www.sobi.com